Bresotec’s BresoDX1 for At-Home Sleep Apnea Testing Receives FDA 510(k) Clearance

Bresotec Medical (“Bresotec” or the “Company”), a medical device company that develops, manufactures, and markets non-invasive portable diagnostic devices for accurate at-home diagnosis of sleep apnea, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) for BresoDX1, its initial product for at-home sleep apnea testing.

BresoDX1 is indicated for use to aid in the diagnosis of moderate to severe sleep apnea in adults in an at-home setting. With only two diagnostic inputs, BresoDX1 records a patient’s physiological signals during sleep, scores apneas and hypopneas, and can be easily and comfortably administered by the patient in a home setting without clinical assistance. Once data is uploaded to the BresoDX1 software, BresoDX1 offers clinicians a reliable, turnkey diagnostic tool with fully transparent reporting.

Polysomnography (PSG) continues to be viewed as the industry standard for sleep apnea diagnosis, but the need for overnight stays in a sleep lab has been insufficient, due to cost and lack of accessibility, to substantially reduce the undiagnosed sleep apnea rate in the United States, with an estimated 80% of sufferers going without diagnosis or treatment. “Over the past several years, the market has experienced a significant shift from in-lab PSG testing to at-home testing,” said Peter Bloch, Chief Executive Officer of Bresotec Medical. “While legacy at-home tests have lowered barriers for patient use, few offer the reliability, ease-of-use, and accuracy of BresoDX1.”

Bresotec Medical founder and Chief Medical Officer, Dr. Douglas Bradley, MD, FRCP, FCAHS, stated that, “Through the collection of tracheal breath sounds and motion, Bresotec’s proprietary technology utilizes respiratory airflow as its primary means of measurement. This unique approach, coupled with strong clinical validation, leaves BresoDX1 uniquely positioned to address the growing, but under-served opportunity in at-home sleep apnea diagnosis.”

With BresoDX1, patients place a sensor on the neck over the trachea (windpipe) and wear a pulse oximeter sensor on the finger. Combined, these inputs record the patient’s tracheal breathing sounds and movements, neck and body position, oxygen saturation (SpO2), and heart rate during sleep. During the test, the data are transmitted wirelessly to a small hub for preprocessing and storing. The data are uploaded from the hub to the cloud where they are analyzed by the BresoDX1 software which generates a comprehensive sleep report showing airflow, respiratory movements, the frequency of apneas and hypopneas and dips in SpO2, body position, and heart rate. The sleep reports are presented in a fully transparent, familiar manner, offering physicians the ability to review, interpret and, if necessary, adjust automated scoring. Bresotec anticipates that reimbursement will be made available through existing CPT code pathways.

Bresotec plans to initiate a controlled, limited launch in the first quarter of 2023 with a full commercial launch set to commence in the third quarter. The company plans to market BresoDX1 through its internal commercial salesforce and will initially target sleep physicians and sleep centers throughout the United States.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy